Chemspeed UK is Evolving
News Oct 17, 2005
The UK subsidiary of Chemspeed Technologies is moving to a new facility at the Northampton Science Park. Centrally located and with close links to the M1, M6 & A14, this specialized office facility will provide an improved level of service and support to all customers and partners.
The facility offers extended meeting room and presentation facilities, more office and product storage space and a 30 square meter chemistry support laboratory. Visitors are welcome at the new offices, starting 1 October 2005, to see some of the latest innovative equipment and accessories in action, and discuss their personal requirements with the Chemspeed team.
Guy Travers will serve as the new Business Manager to implement the transition to the expanded facilities and manage the growth of new technologies in the UK. Having worked for companies supplying equipment to the Pharmaceutical & Fine Chemical Industry of the UK for more than 10 years, Mr. Travers has extensive experience in the market.
Since 2000, he has been involved with the implementation of automated solutions for many companies and brings with him first-hand knowledge and know-how.
Richard Giles has been appointed to head the chemistry support services in the UK. Mr. Giles received his Ph.D. at Durham University, where he was responsible for implementing the automated development of bi-functional catalysts. He previously worked at the Process Research department at GSK (Tonbridge) and has published frequently in the Journal of Organometallic Chemistry. His professional experience will facilitate the ease of implementation of new technologies into specialized workflows.
U.S. Study of Dapivirine Ring in Lactating Women Finds Little Drug Gets Into Breast MilkNews
The antiretroviral drug dapivirine that is released from an experimental vaginal ring to protect against HIV is absorbed in very low concentrations into breastmilk.READ MORE
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Bone Cancer Drug Targets Tumors, Spares Other OrgansNews
A study led by The University of Texas MD Anderson Cancer Center found a drug known as bone metastasis-targeting peptidomimetic (BMTP-11) has potential as a new therapeutic strategy for this devastating illness.READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018